Boston, Mass. – February 21, 2014 – Cooley LLP announced today that it advised the underwriters on Genocea Biosciences, Inc.'s initial public offering. Genocea Biosciences is harnessing the power of T cell immunity to develop the next generation of vaccines. It now trades on the NASDAQ Global Stock Market under the symbol "GNCA."
Citigroup and Cowen and Company acted as joint book-running managers for the offering. Stifel acted as lead manager and Needham & Company, LLC acted as co-manager.
The Cooley corporate securities team was comprised of partner and chair of the life sciences practice Barbara Kosacz, partners Marc Recht and Nicole Brookshire and associates Giselle Rivers and Natalie Linendoll. Critical support for the offering was provided by partners Natasha Leskovsek and Wendy Goldstein, special counsel Phil Mitchell and associate Jennifer Shanley (health care and life sciences regulatory); associate Keith Ranta (compensation and benefits); associates Mark Hayman and Karen Won (intellectual property)and partner Ken Krisko and associate Jennifer Raab (life sciences licensing).
This offering follows Cooley's record year in 2013 for capital markets in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 22 completed public offerings, including 12 completed IPOs.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 750 lawyers across 11 offices in the United States and China.